Skyhawk Therapeutics Announces Nine Month Interim Results in Patients from its Phase 1 Clinical Trial of SKY-0515 as a Treatment for Huntington's Disease

Treatment with SKY-0515 results in dose-dependent reductions of mHTT protein in blood of 62% at the 9mg dose, and dose-dependent PMS1 mRNA reduction of 26%. PMS1 is a key driver of somatic CAG repeat ...

Zomedica Corp. (ZOMDF) Discusses Technology and Digital Innovation Driving Growth in Animal Health Transcript

Discusses Technology and Digital Innovation Driving Growth in Animal Health January 23, 2026 4:00 PM ESTCompany ...

EQS-News: Skyhawk Therapeutics Announces Nine Month Interim Results in Patients from its Phase 1

Treatment with SKY-0515 results in dose-dependent reductions of mHTT protein in blood of 62% at the 9mg dose, and dose-dependent PMS1 mRNA reduction of 26%. PMS1 is a key driver of somatic CAG repeat ...
Scientific Research Publishing

Legal Environment and SACCOS Financial Performance in Mbeya, Tanzania: Mediated by Corporate Governance ()

Legal Environment, Corporate Governance, Financial Performance, SACCOS, Institutional Theory Share and Cite: Mbegu, S. (2026) Legal Environment and SACCOS Financial Performance in Mbeya, Tanzania: ...
IEEE

FedEXT: Differential Federated Learning with Complementary Extension of Edge Models

Abstract: We introduce FedEXT, an innovative federated learning framework designed to address the challenges of platforms with limited communication and computational resources. FedEXT employs a ...